Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.

Biotech SG&A Expenses: Vertex vs. Viridian

__timestampVertex Pharmaceuticals IncorporatedViridian Therapeutics, Inc.
Wednesday, January 1, 20143054090007751000
Thursday, January 1, 201537708000010251000
Friday, January 1, 20164328290009575000
Sunday, January 1, 201749607900010912000
Monday, January 1, 201855761600011049000
Tuesday, January 1, 201965849800011646000
Wednesday, January 1, 202077045600013265000
Friday, January 1, 202184010000025805000
Saturday, January 1, 202294470000035182000
Sunday, January 1, 2023113660000094999000
Monday, January 1, 20241464300000
Loading chart...

Unlocking the unknown

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Vertex Pharmaceuticals Incorporated and Viridian Therapeutics, Inc. from 2014 to 2023. Vertex Pharmaceuticals, a leader in the industry, has seen its SG&A expenses grow by approximately 272% over this period, reflecting its expanding operations and market reach. In contrast, Viridian Therapeutics, a smaller player, has experienced a staggering increase of over 1,125% in SG&A expenses, indicating rapid growth and investment in its business infrastructure.

Key Insights

  • Vertex Pharmaceuticals: Consistent growth in SG&A expenses, peaking in 2023.
  • Viridian Therapeutics: Significant rise in expenses, especially notable in recent years.

This data highlights the dynamic nature of the biotech sector, where strategic spending can drive innovation and market leadership.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025